Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT07090876

Hemodynamic Effects of a Standardized Grape Seed Extract Supplementation

Hemodynamic Effects of a Standardized Grape Seed Extract Supplementation: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial

Status
Not Yet Recruiting
Phase
N/A
Study type
Interventional
Enrollment
60 (estimated)
Sponsor
Indena S.p.A · Industry
Sex
All
Age
18 Years – 70 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to evaluate whether a standardized grape seed extract, compared to placebo, can significantly influence systolic blood pressure (SBP) in individuals with high-normal blood pressure (BP) who are adhering to a low-sodium Mediterranean diet. Additionally, the effects of the grape seed extract on diastolic blood pressure (DBP), other hemodynamic parameters, and the Perceived Stress Score will be assessed.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTStandardized Grape Seed ExtractGrape seed dry extract standardized to provide: ≥95.0% of proanthocyanidins by spectrophotometry, ≥5.0% ≤15.0% of catechin and epicatechin by High-Performance Liquid Chromatography (HPLC)
OTHERPlaceboPlacebo

Timeline

Start date
2025-12-01
Primary completion
2027-01-30
Completion
2027-01-30
First posted
2025-07-29
Last updated
2025-11-20

Locations

1 site across 1 country: Italy

Source: ClinicalTrials.gov record NCT07090876. Inclusion in this directory is not an endorsement.